Has Majid Torabi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,392 in general payments to Majid Torabi, MD across 148 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Majid Torabi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Majid Torabi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Majid Torabi, MD

Otolaryngology · Rancho Mirage, CANPI 1598721474

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations.

$4,392in general payments, 2019–2025

Across 148 payments — averaging $29.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$958
GSK$572
CSL Behring$424
Takeda Pharmaceuticals U.S.A., Inc.$301
AstraZeneca$246
Genentech USA, Inc.$203
plus $2K from 23 others

What the payments were for

Food & beverage$4,35699%
Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	31	$958
GSK	34	$572
CSL Behring	15	$424
Takeda Pharmaceuticals U.S.A., Inc.	8	$301
AstraZeneca	5	$246
Genentech USA, Inc.	5	$203
Integra Lifesciences Corporation	3	$197
Pharming Healthcare, Inc.	5	$168
Optinose US, Inc.	7	$157
BD	1	$155
Hologic Sales And Service, LLC	2	$153
Acclarent, Inc	2	$133
Biocryst US Sales Co., LLC	3	$131
Shire North American Group Inc	9	$116
Ionis Pharmaceuticals, Inc.	2	$61
Smith+Nephew	2	$56
Aerin Medical Inc.	1	$51
Stryker	1	$42
EMD Serono, Inc.	1	$37
Regeneron Healthcare Solutions, Inc.	1	$34
Merck	2	$32
Phathom Pharmaceuticals, Inc.	1	$29
Itamar Medical Inc	1	$23
Amgen	1	$23
Phadia US Inc.	1	$22
Davol Inc.	1	$19
Neurent Medical Limited	1	$17
Biohaven Pharmaceuticals, Inc.	1	$17
Kaleo, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,392 in reported general payments places this provider in the 80th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California →

Medicare billing

Part B allowed, 2024

$388,015

Medicare patients

804

Services billed

10,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Azelastine Hcl	430	$10,489
Epinephrine	33	$7,408
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth	57	$5,403
Fluticasone Propionate	449	$4,980
Montelukast Sodium	176	$2,370
Ipratropium Bromide	77	$2,059
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	121	$2,014
Famotidine	113	$1,450
Omeprazole	121	$1,433
Mometasone Furoate	79	$948
Mupirocin	142	$920
Clotrimazole	28	$800
Doxycycline Hyclate	34	$703
Triamcinolone Acetonide	30	$631
Fluocinolone Acetonide Oil	18	$469

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Rancho Mirage

Brian WeeksSan Diego$924K
Randall OwRoseville$613K
Amir MoradiVista$389K
Keith BlackwellLos Angeles$349K
Kalpna DurairajSun Valley$348K
Todd MillerNewport Beach$259K
Jeffrey SuhLos Angeles$223K
Dennis TangLos Angeles$209K
Jeffrey FeinfieldThousand Oaks$160K
Jonathan SykesGranite Bay$148K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →